From FB/YMB Fund Raising Dear Fellow Share
Post# of 148192
(Total Views: 857)
Posted On: 01/11/2022 9:07:01 PM
From FB/YMB
Fund Raising
Dear Fellow Shareholders,
My name is A. Balikcioglu. I am a double board-certified gastroenterologist and internist by the American Board of Internal Medicine and Gastroenterology. I am affiliated with multiple hospitals in the New York area, including Mt. Sinai Hospital and Montefiore Medical Center. I have been in practice for over 20 years and I am qualified in the cutting-edge developments of my field.
I am writing to you as a long shareholder of CytoDyn (CYDY). I am a steadfast believer in the tremendous potential of the company’s drug, Leronlimab, a monoclonal antibody CCR5 receptor antagonist, to be used as a platform drug for variety of indications. I believe that this is a revolutionary drug and is positioned to be the next generation of medication. If the company is successful in securing US FDA approval of any current studies, including HIV BLA, many lives will be saved and tremendous value will be created for the company’s stockholders.
Over the past months, there have been scare-mongering hysterics about the company that are substantially unfounded and aimed to distract stockholders from the facts. There are a lot of people and big players who are actively working against CytoDyn by manipulating its stock through the dissemination of inaccurate and fake news about the company. Big pharma knows and understands the value of CytoDyn’s medication once it gets FDA approval. They want this late-stage biotechnology company to fail so that they can take over CytoDyn for almost nothing.
Leronlimad continues to meet expectations and it is just a matter of time before it receives US FDA approval. The effects of market volatility, speculation, and malicious manipulation by a lot of people and companies — which stand to gain if CytoDyn fails — has disproportionately affected the company’s stocks (CYDY). I strongly believe that this a short-term phase and is not representative of the actual financial value of CytoDyn with the success of its revolutionary drug. The company just needs some time to get this medication FDA approved. But, the malicious manipulation that has caused the stock to drop is affecting the company and paralyzing it from doing anything. Any company or individual who, directly or indirectly, try to prevent this drug from being approved should be criminally charged because they are preventing patients from getting life-saving treatment and putting their own financial gain over the lives of these patients.
The biggest challenge we are dealing with right now is this short term drop of CYDY value which threatens the long-term viability and success of the company’s operations and Leronlimab’s achievement of its full potential. As a fellow long position shareholder, I am reaching out to you to proactively ensure that our investments and belief in the potential of the company to create significant value for its shareholders is not upended. In my opinion, we have two choices on how to deal with this short-term drop in the CYDY stock value: we either allow the company to go bankrupt, or we actively save the company by raising enough funds for the company’s operations to continue.
We need to bond together as a group to capitalize on the significant opportunities that can be gained from Leronlimab’s potential to unlock substantial value for all stockholders. I propose that each of us, shareholders, raise enough fund to keep the company afloat during this challenging period. We can discuss further details on how we can do it in a group Zoom meeting. For example, if 3000 shareholders directly invest on average $20,000.00, we will be able to easily raise $60,000,000.00 to ensure the financial stability of CytoDyn and to propel its growth. This money will have 2 effects: 1) the company will have sufficient capital to function and operate for at least a year; 2) it will ease the concerns of more shareholders about the stability of the company, causing them to buy more stocks and invest further.
Of course, we will make sure that the money we will raise would be controlled by a small group directly chosen by us through a serious selection of individuals, who are professionally knowledgeable about finance and biotech companies, such as CPAs, lawyers, and investment professionals. The money could also be provided directly to CytoDyn in exchange for future stocks or financial interests. After we raise an “X” amount of money, we can meet with the executives of CytoDyn to discuss the procedures and terms before releasing it to the company.
If you have any doubts about my credentials, please feel free to Google my information.
The contents of this letter and my recommendations are solely my own thoughts and solution. They do not represent the opinions of any hospitals I am affiliated with. I did not take part, nor do I have any access to any of the research done in connection with CytoDyn’s drug.
Sincerely,
A. Balikcioglu, M.D.
(Copied from Facebook)
Fund Raising
Dear Fellow Shareholders,
My name is A. Balikcioglu. I am a double board-certified gastroenterologist and internist by the American Board of Internal Medicine and Gastroenterology. I am affiliated with multiple hospitals in the New York area, including Mt. Sinai Hospital and Montefiore Medical Center. I have been in practice for over 20 years and I am qualified in the cutting-edge developments of my field.
I am writing to you as a long shareholder of CytoDyn (CYDY). I am a steadfast believer in the tremendous potential of the company’s drug, Leronlimab, a monoclonal antibody CCR5 receptor antagonist, to be used as a platform drug for variety of indications. I believe that this is a revolutionary drug and is positioned to be the next generation of medication. If the company is successful in securing US FDA approval of any current studies, including HIV BLA, many lives will be saved and tremendous value will be created for the company’s stockholders.
Over the past months, there have been scare-mongering hysterics about the company that are substantially unfounded and aimed to distract stockholders from the facts. There are a lot of people and big players who are actively working against CytoDyn by manipulating its stock through the dissemination of inaccurate and fake news about the company. Big pharma knows and understands the value of CytoDyn’s medication once it gets FDA approval. They want this late-stage biotechnology company to fail so that they can take over CytoDyn for almost nothing.
Leronlimad continues to meet expectations and it is just a matter of time before it receives US FDA approval. The effects of market volatility, speculation, and malicious manipulation by a lot of people and companies — which stand to gain if CytoDyn fails — has disproportionately affected the company’s stocks (CYDY). I strongly believe that this a short-term phase and is not representative of the actual financial value of CytoDyn with the success of its revolutionary drug. The company just needs some time to get this medication FDA approved. But, the malicious manipulation that has caused the stock to drop is affecting the company and paralyzing it from doing anything. Any company or individual who, directly or indirectly, try to prevent this drug from being approved should be criminally charged because they are preventing patients from getting life-saving treatment and putting their own financial gain over the lives of these patients.
The biggest challenge we are dealing with right now is this short term drop of CYDY value which threatens the long-term viability and success of the company’s operations and Leronlimab’s achievement of its full potential. As a fellow long position shareholder, I am reaching out to you to proactively ensure that our investments and belief in the potential of the company to create significant value for its shareholders is not upended. In my opinion, we have two choices on how to deal with this short-term drop in the CYDY stock value: we either allow the company to go bankrupt, or we actively save the company by raising enough funds for the company’s operations to continue.
We need to bond together as a group to capitalize on the significant opportunities that can be gained from Leronlimab’s potential to unlock substantial value for all stockholders. I propose that each of us, shareholders, raise enough fund to keep the company afloat during this challenging period. We can discuss further details on how we can do it in a group Zoom meeting. For example, if 3000 shareholders directly invest on average $20,000.00, we will be able to easily raise $60,000,000.00 to ensure the financial stability of CytoDyn and to propel its growth. This money will have 2 effects: 1) the company will have sufficient capital to function and operate for at least a year; 2) it will ease the concerns of more shareholders about the stability of the company, causing them to buy more stocks and invest further.
Of course, we will make sure that the money we will raise would be controlled by a small group directly chosen by us through a serious selection of individuals, who are professionally knowledgeable about finance and biotech companies, such as CPAs, lawyers, and investment professionals. The money could also be provided directly to CytoDyn in exchange for future stocks or financial interests. After we raise an “X” amount of money, we can meet with the executives of CytoDyn to discuss the procedures and terms before releasing it to the company.
If you have any doubts about my credentials, please feel free to Google my information.
The contents of this letter and my recommendations are solely my own thoughts and solution. They do not represent the opinions of any hospitals I am affiliated with. I did not take part, nor do I have any access to any of the research done in connection with CytoDyn’s drug.
Sincerely,
A. Balikcioglu, M.D.
(Copied from Facebook)
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼